An Open-Label, 2-Part Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet.

Trial Profile

An Open-Label, 2-Part Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Pictrelisib (Primary) ; Ketoconazole
  • Indications Acute myeloid leukaemia; Breast cancer; Multiple myeloma; Mycoses; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 19 Jul 2012 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov record.
    • 03 Dec 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top